| p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53 K Oda, H Arakawa, T Tanaka, K Matsuda, C Tanikawa, T Mori, ... Cell 102 (6), 849-862, 2000 | 1527 | 2000 |
| High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma K Oda, D Stokoe, Y Taketani, F McCormick Cancer research 65 (23), 10669-10673, 2005 | 580 | 2005 |
| PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation K Oda, J Okada, L Timmerman, P Rodriguez-Viciana, D Stokoe, K Shoji, ... Cancer research 68 (19), 8127-8136, 2008 | 213 | 2008 |
| Genome-wide cDNA microarray analysis of gene-expression profiles involved in ovarian endometriosis T Arimoto, T Katagiri, K Oda, T Tsunoda, T Yasugi, Y Osuga, H Yoshikawa, ... International journal of oncology 22 (3), 551-560, 2003 | 185 | 2003 |
| Resveratrol promotes expression of SIRT1 and StAR in rat ovarian granulosa cells: an implicative role of SIRT1 in the ovary Y Morita, O Wada-Hiraike, T Yano, A Shirane, M Hirano, H Hiraike, ... Reproductive Biology and Endocrinology 10, 1-10, 2012 | 173 | 2012 |
| The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas K Shoji, K Oda, S Nakagawa, S Hosokawa, G Nagae, Y Uehara, K Sone, ... British journal of cancer 101 (1), 145-148, 2009 | 171 | 2009 |
| PTEN Mutation Located Only Outside Exons 5, 6, and 7 Is an Independent Predictor of Favorable Survival in Endometrial Carcinomas T Minaguchi, H Yoshikawa, K Oda, T Ishino, T Yasugi, T Onda, ... Clinical cancer research 7 (9), 2636-2642, 2001 | 142 | 2001 |
| Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management K Oda, J Hamanishi, K Matsuo, K Hasegawa Gynecologic oncology 151 (2), 381-389, 2018 | 131 | 2018 |
| Cancer targets in the Ras pathway P Rodriguez-Viciana, O Tetsu, K Oda, J Okada, K Rauen, F McCormick Cold Spring Harbor symposia on quantitative biology 70, 461-467, 2005 | 130 | 2005 |
| Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients K Kawana, K Adachi, S Kojima, A Taguchi, K Tomio, A Yamashita, ... Vaccine 32 (47), 6233-6239, 2014 | 127 | 2014 |
| Cloning and characterization of BAI-associated protein 1: a PDZ domain-containing protein that interacts with BAI1 T Shiratsuchi, M Futamura, K Oda, H Nishimori, Y Nakamura, T Tokino Biochemical and biophysical research communications 247 (3), 597-604, 1998 | 117 | 1998 |
| Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against … K Adachi, K Kawana, T Yokoyama, T Fujii, A Tomio, S Miura, K Tomio, ... Vaccine 28 (16), 2810-2817, 2010 | 110 | 2010 |
| Identification of BAIAP2 (BAI-associated protein 2), a novel human homologue of hamster IRSp53, whose SH3 domain interacts with the cytoplasmic domain of BAI1 K Oda, T Shiratsuchi, H Nishimori, J Inazawa, H Yoshikawa, Y Taketani, ... Cytogenetics and cell genetics 84 (1-2), 75-82, 1999 | 108 | 1999 |
| Clear cell carcinoma of the ovary K Fujiwara, K Oda, M Takano, N Matsumura Textbook of Uncommon Cancer, 550-556, 2017 | 106 | 2017 |
| Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations S Inoue, Y Hirota, T Ueno, Y Fukui, E Yoshida, T Hayashi, S Kojima, ... Nature communications 10 (1), 5785, 2019 | 96 | 2019 |
| Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas K Shoji, K Oda, T Kashiyama, Y Ikeda, S Nakagawa, K Sone, Y Miyamoto, ... PloS one 7 (5), e37431, 2012 | 96 | 2012 |
| Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers K Kawana, T Yasugi, T Kanda, N Kino, K Oda, S Okada, Y Kawana, T Nei, ... Vaccine 21 (27-30), 4256-4260, 2003 | 96 | 2003 |
| The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition T Fukuda, K Oda, O Wada-Hiraike, K Sone, K Inaba, Y Ikeda, A Miyasaka, ... Gynecologic oncology 137 (3), 538-545, 2015 | 89 | 2015 |
| β-catenin (CTNNB1) S33C mutation in ovarian microcystic stromal tumors D Maeda, J Shibahara, T Sakuma, M Isobe, S Teshima, M Mori, K Oda, ... The American journal of surgical pathology 35 (10), 1429-1440, 2011 | 85 | 2011 |
| Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup I Vergote, A Gonzalez-Martin, D Lorusso, C Gourley, MR Mirza, JE Kurtz, ... The Lancet Oncology 23 (8), e374-e384, 2022 | 84 | 2022 |
KAZUNORI NAGASAKADepartment of Obstetrics and Gynecology, The University of Tokyo在 umin.ac.jp 的电子邮件经过验证
